H H Lundbeck A-S
H
Atidarymo kaina
41.74 1.36
Apžvalga
Akcijų kainos pasikeitimas
24 val.
Min
41.04
Max
42.32
Pajamos | 1.7B 1.7B |
|---|---|
Pardavimai | 1.2B 7B |
P/E Sektoriaus vid. | 10.676 49.701 |
Pelnas, tenkantis vienai akcijai | 0.94 |
Dividendų pajamingumas | 2.78 |
Pelno marža | 23.601 |
Darbuotojai | 5,000 |
EBITDA | 598M 2.4B |
Dividendų pajamingumas Sektoriaus vid. | 2.78% 2.39% |
|---|
Rinkos kapitalizacija | -2.1B 40B |
|---|---|
Ankstesnė atidarymo kaina | 40.38 |
Ankstesnė uždarymo kaina | 41.74 |
H Lundbeck A-S Grafikas
Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.
Susijusios naujienos
Akcijų palyginimas
Kainos pokytis
H Lundbeck A-S Prognozė
Finansinės naujienos
Pardavimo ir administravimo išlaidos
Veiklos sąnaudos
Ikimokestinis pelnas
Pardavimai
Pardavimo savikaina
Bendrasis pelnas iš pardavimo
Skolų palūkanų išlaidos
EBITDA
Veiklos pelnas
$
Apie bendrovę H Lundbeck A-S
H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company's principal products include Abilify Maintena/Abilify Maintena for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat MDD and schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat dementia; Onfi for epilepsy; Sabril for the treatment of refractory complex partial seizures and infantile spasms; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol to treat psychosis. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership collaboration with Otsuka Pharmaceuticals Co., Ltd.; and collaboration with Alloy Therapeutics, Inc. for the discovery of novel biologics therapies. The company was founded in 1915 and is headquartered in Valby, Denmark.
